The Latest Breaking News on After US approval, Japan OKs its first Alzheimer's drug. Leqembi was developed by Eisai and Biogen

The first drug found to slow the progression of Alzheimer's disease has been granted full approval by the Food and Drug Administration.

The drug Leqembi targets plaque buildup in the brain, and it is approved for people in the early stages of the disease.

Leqembi could become the first treatment of its kind to receive traditional approval from the FDA.

U.S. health advisers are backing the full approval of an Alzheimer's drug that received preliminary approval last year

The new Alzheimers drug is the first preventative treatment for the disease - previous medications have only tackled symptoms of dementia, and has been hailed as ground-breaking

There are now two impressive possible treatments for this form of dementia. But concerns remain over cost and potential side-effects, says Devi Sridhar, chair of global public health at the University of Edinburgh

The discovery of a gene variant that protects against an early, insidious form of Alzheimer's could lead to new treatments for the disease.

Donanemab was shown in a late-stage trial to slow cognitive decline more than a third

American pharmaceutical company Eli Lilly announced last week that it had seen encouraging clinical trial results of its new Alzheimer’s medication. According to the company, their experimental drug, donanemab, was shown in a late-stage trial to slow cognitive decline by 35%. While these results do sound promising, the full data…